Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Bioorganic chemistry (Print)

• Publication date

  2018-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bioorg.2018.01.034PMID 29453076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies.

  2017cited by this paper
• New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres

  2017cited by this paper
• Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents

  2017cited by this paper
• PARP inhibitors: the race is on

  2016cited by this paper
• Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.

  2016cited by this paper
• Synthesis, Crystal Study, and Anti-Proliferative Activity of Some 2-Benzimidazolylthioacetophenones towards Triple-Negative Breast Cancer MDA-MB-468 Cells as Apoptosis-Inducing Agents

  2016cited by this paper
• PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

  2016cited by this paper
• PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair

  2016cited by this paper
• Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.

  2016cited by this paper
• 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.

  2016cited by this paper
• Design, Synthesis and In Vitro Antiproliferative Activity of Novel Isatin‐Quinazoline Hybrids

  2015cited by this paper
• PTEN and PI3K/AKT in non-small-cell lung cancer.

  2015cited by this paper
• Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones.

  2015cited by this paper
• PARP1 Inhibitors: antitumor drug design

  2015cited by this paper
• Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.

  2014cited by this paper
• Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cited by this paper
• Beyond DNA Repair: Additional Functions of PARP-1 in Cancer

  2013cited by this paper
• Cell Survival and Apoptosis Signaling as Therapeutic Target for Cancer: Marine Bioactive Compounds

  2013cited by this paper
• The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis

  2013cited by this paper
• A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

  2013cited by this paper
• Molecular Dissection of AKT Activation in Lung Cancer Cell Lines

  2013cited by this paper
• PARP inhibitors in lung cancer.

  2012cited by this paper
• Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase

  2012cited by this paper
• Mitochondria and cancer

  2012cited by this paper
• PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.

  2011cited by this paper
• Roles of AKT1 and AKT2 in non‐small cell lung cancer cell survival, growth, and migration

  2011cited by this paper
• Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

  2010cited by this paper
• Targeting mitochondria for cancer therapy

  2010cited by this paper
• PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.

  2010cited by this paper
• 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

  2008cited by this paper
• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  2008cited by this paper
• Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

  2007cited by this paper
• Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.

  2006cited by this paper
• Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

  2005cited by this paper
• Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.

  2005cited by this paper
• Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.

  2004cited by this paper
• Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases.

  2004cited by this paper
• Phospho-Akt Overexpression in Non–Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage

  2004cited by this paper
• Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

  2004cited by this paper
• Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling.

  2002cited by this paper
• Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

  1999cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors

  2025cites this paper
• Aqueous micellar catalysis for the efficient synthesis of chromeno-pyrazolo[1,2-b]phthalazines and indazolo[1,2-b]phthalazines, their plausible therapeutic implications and DFT investigations

  2025cites this paper
• Anticancer potential of 2,2′-bipyridine hydroxamic acid derivatives in head and neck cancer therapy

  2025cites this paper
• A convenient metal-free one-pot synthesis of some phthalazine derivatives mediated by 3-picolinic acid

  2025cites this paper
• Therapeutic approach for triple-negative breast Cancer through poly (ADP-ribose) Polymerase-1 inhibitors: Current update.

  2025cites this paper
• Computational design of PARP-1 inhibitors: QSAR, molecular docking, virtual screening, ADMET, and molecular dynamics simulations for targeted drug development

  2025cites this paper
• Design, synthesis, biological evaluation, and molecular modeling simulations of new phthalazine‐1,4‐dione derivatives as anti‐Alzheimer's agents

  2024cites this paper
• Pyridazinone: A privileged scaffold for synthetic and biomedical applications

  2024cites this paper
• The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancer

  2024cites this paper
• Microwave-assisted synthesis, characterization, and molecular docking studies of new chlorophthalazine derivatives as anticancer activity

  2024cites this paper
• An overview of pyridazin-3(2H)-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer.

  2024cites this paper
• Patents on PARP-1 Inhibitors for the Management of Cancer from 2017-2023.

  2024cites this paper
• Pyridazine Based Compounds with PARP-1 Inhibitory Activity

  2023cites this paper
• Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship.

  2023cites this paper
• Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies

  2023cites this paper
• An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs.

  2023cites this paper
• Synthesis of Some New Phthalazine−piperazine−pyrazole Conjugates; In vitro Anti‐Cancer, ADMET And Molecular Docking Studies

  2023cites this paper
• Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates

  2023cites this paper
• Design, synthesis, and evaluation of 1H‐benzo[d]imidazole‐4‐carboxamide PARP‐1 inhibitors using different saturated nitrogen‐contained heterocycle as linker group

  2023influential citation
• Recent Progress of the research on the benzimidazole PARP-1 inhibitors.

  2022cites this paper
• Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment.

  2022cites this paper
• Terminalia chebula Polyphenol and Near-Infrared Dye-Loaded Poly(lactic acid) Nanoparticles for Imaging and Photothermal Therapy of Cancer Cells.

  2022cites this paper
• The capable xanthine-based adsorbent for removal of the Cd(II), Ni(II) and Pb(II) ions from aqueous solution via their complexation and the use of its corresponding Cd complex for the green synthesis of indazolophthalazinetriones

  2022cites this paper
• Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells

  2022cites this paper
• Novel Phthalazin-1(2H)-One Derivatives Displaying a Dithiocarbamate Moiety as Potential Anticancer Agents

  2022cites this paper
• Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy.

  2022cites this paper
• Cytotoxic Activity, Apoptosis Induction and Structure–Activity Relationship of 2‐Phenylphthalazin‐2‐ium Salts as Promising Antitumor Agents

  2022cites this paper
• Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells

  2021cites this paper
• Synthesis, structural characterization, and molecular docking study of new phthalhydrazide-coumarin hybrids

  2021cites this paper
• Discovery of pyrano[2,3-d]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity

  2021cites this paper
• Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.

  2021cites this paper
• Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer

  2021influential citation
• 1,3,4-Oxadiazole-containing hybrids as potential anticancer agents: Recent developments, mechanism of action and structure-activity relationships

  2021cites this paper
• Simple Thalidomide Analogs in Melanoma: Synthesis and Biological Activity

  2021cites this paper
• Systems pharmacology to reveal multi-scale mechanisms of traditional Chinese medicine for gastric cancer

  2021cites this paper
• Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.

  2020cites this paper
• Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.

  2020cites this paper
• Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules.

  2020cites this paper
• DDDT_A_252112 1885..1895

  2020cites this paper
• Phthalazinone Scaffold:Emerging Tool in the Development of Target Based Novel Anticancer Agents.

  2020cites this paper
• Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents

  2020cites this paper
• Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.

  2020cites this paper
• Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects.

  2020cites this paper
• TRIAZOLOPHTHALAZINE INCORPORATING PIPERAZINE DERIVATIVES: SYNTHESIS AND IN VITRO ANTICANCER EVALUATION STUDY

  2020cites this paper
• Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy.

  2020cites this paper
• Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.

  2020cites this paper
• Design, synthesis, molecular docking and antiproliferative activity of some novel benzothiazole derivatives targeting EGFR/HER2 and TS.

  2020cites this paper
• Leonurine Promotes Cisplatin Sensitivity in Human Cervical Cancer Cells Through Increasing Apoptosis and Inhibiting Drug-Resistant Proteins

  2020cites this paper
• Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies.

  2020cites this paper
• 4-Anilino Quinazoline Derivatives: Molecular Docking and Evaluation of In vitro Cytotoxic Activity

  2020cites this paper
• Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety

  2020cites this paper
• Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.

  2020cites this paper
• Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents

  2019cites this paper
• Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.

  2019cites this paper
• Pharmacological activities of various phthalazine and phthalazinone derivatives

  2019cites this paper
• Brief Overview on Biological Potential of Various Substituted Phthalazine and Phthalazinone Analogues

  2019cites this paper
• "A Sweet Combination": Developing saccharin and acesulfame K structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII.

  2019cites this paper
• Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs.

  2019cites this paper
• Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.

  2019cites this paper
• Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.

  2019cites this paper
• Synthesis, biological evaluation and in silico studies with 4-benzylidene-2-phenyl-5(4H)-imidazolone-based benzenesulfonamides as novel selective carbonic anhydrase IX inhibitors endowed with anticancer activity.

  2019cites this paper
• Novel Diamide-Based Benzenesulfonamides as Selective Carbonic Anhydrase IX Inhibitors Endowed with Antitumor Activity: Synthesis, Biological Evaluation and In Silico Insights

  2019cites this paper
• Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer

  2019cites this paper
• Facile Synthesis of 2,2-Diacyl Spirocyclohexanones via an N-Heterocyclic Carbene-Catalyzed Formal [3C + 3C] Annulation.

  2019cites this paper
• Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies

  2018cites this paper
• Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer.

  2018cites this paper
• Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation

  2018cites this paper
• Synthesis of 5-(5-amino-1H-pyrazol-1-yl)-1,2,3-thiadiazole-4-carboxylic acid ethyl esters and their cyclization into pyrazolo[1,5-a][1,2,3]thiadiazolo[4,5-e]pyrimidin-4(5H)-ones

  2018cites this paper